AstraZeneca's Imfinzi Combo Gets FDA Priority Review for Bladder Cancer

FDA grants priority review to AstraZeneca's Imfinzi (durvalumab) plus enfortumab vedotin for muscle-invasive bladder cancer patients ineligible for cisplatin. This accelerates regulatory decision timeline, potentially expanding treatment options. Approval would strengthen AstraZeneca's oncology portfolio, but market impact is limited as it's a regulatory milestone, not a clinical data release.